The NSCLC Content Hub Channel

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow recommends next-generation sequencing to find targeted mutations for ALK-rearranged lung cancer patients. Dr. Rotow also recommends ALK-inhibitors alectinib and brigatinib for patients with limited CNS disease for more systemic control.

Learn more by clicking here.

More in NSCLC Content Hub

► 1:15

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

NSCLC Content Hub

Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation identification is...

► 1:20

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

NSCLC Content Hub

Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center - James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved EGFR tyrosine...

► 3:51

Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer

NSCLC Content Hub

Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations...

► 1:38

Molecular Testing Used for Patients With Non-Small Cell Lung Cancer

NSCLC Content Hub

Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous non-small cell...